A novel precision medicine approach to optimise treatment for ovarian cancer
Ovarian cancer with peritoneal metastases is associated with a poor prognosis, and intraperitoneal therapies such as hyperthermic intraperitoneal chemotherapy (HIPEC) have demonstrated survival benefits, but only in some patients. In their study, published in JCO Precision Oncology, Dr Dellinger and colleagues used whole-transcriptome sequencing to identify distinct molecular signatures in HIPEC responders versus non-responders. This innovative approach could help to identify ovarian cancer patients who would respond to HIPEC versus those who would not. This novel precision medicine approach offers the potential to improve patient outcomes by personalising treatment.
Read more about this exciting work
At Whipbird Communications, we specialise in the clear communication of science and medicine, providing comprehensive medical writing support on scientific and medical manuscripts, to increase the likelihood of success in publishing your scientific and medical studies.